Sciety has quickly become a prominent player within investments in unlisted life science companies in the Nordics. Founded in 2016 by Andreas Lindblom and Malin Lindblom, Sciety was born from the idea of helping investors find good companies in life science—a field that typically requires industry knowledge. Hear from the
INSIGHT. Women’s health issues have traditionally been underfunded and under-researched but in recent years there has been a growing recognition of the importance of women’s health and the potential for market growth. The White House and the First Lady of the United States, Dr. Jill Biden, recently announced an allocation
INSIGHT. In February this year, the FDA approved the first T cell therapy against solid tumours—lifileucel. This method utilises tumour-infiltrating lymphocytes (TIL), a type of T cell naturally targeting cancer cells, extracted from the patient’s own tumour and then multiplied in a laboratory environment. Ultimately, the cells are reintroduced to
INSIGHT. Ice baths, meditation, regular exercise, sleep optimisation and drugs such as metformin and ozempic—the list of so-called biohacking tips and methods for those who want to optimise their health and longevity is long. The interest in longevity—the science of extending lifespan and improving quality of life—is growing rapidly, attracting
PRESS RELEASE. Sciety and Sciety Venture Partners have recently completed an investment of about EUR 1.35 million in Capitainer, a Swedish medtech company that has developed unique products for self-sampling of blood from the fingertip. The funds will be used to expand production and strengthen the company’s sales organisation in
At Sciety, we believe that the impact of scientific advancements should not be limited to the lab. This is why we support selected, innovative companies in life science and digital health. With deep expertise in life science, we are a long-term partner to prominent growth companies in the industry. Sciety